Hoth Therapeutics, Inc.

As of June 17, 2025, the market trend is neutral with mixed signals: weekly indicators are bullish, monthly RSI is bearish, and daily moving averages show short-term weakness, reflecting overall uncertainty.

Hoth Therapeutics, Inc. is a micro-cap biopharmaceutical company focused on developing targeted therapeutics for conditions like atopic dermatitis. As of March 2025, it reported a net profit loss of $3 million and has a market cap of $17.17 million.

As of Jun 18, Hoth Therapeutics, Inc. has a market capitalization of 17.17 million, with net sales of 0.00 million and a net profit of -9.62 million over the last four quarters. The company reported shareholder's funds of 6.88 million and total assets of 7.71 million as of Dec 24.